Anmeldung erfolgt in Kürze...
Details werden geladen...
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program | The Manila Times
White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
Ähnliche Seiten
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | The Manila Times
https://www.manilatimes.net/2026/04/24/tmt-newswire/globenewswire/fda-approves-first-ever-gene-therapy-for-treatment-of-genetic-hearing-loss-under-national-priority-voucher-program/2327730
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucherANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity | The Manila Times
https://www.manilatimes.net/2026/04/20/tmt-newswire/globenewswire/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-pimozide-tablets-with-180-day-cgt-exclusivity/2323801Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program | The Manila Times
https://www.manilatimes.net/2026/05/05/tmt-newswire/globenewswire/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program/2335437Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/03/21/tmt-newswire/globenewswire/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2304724